Global Beauty Market Grows 10% as AI and E-commerce Reshape Consumer Buying
1.4.2026 03:00:00 CEST | Business Wire | Press Release
NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its State of Beauty 2026 report, showing the global beauty market grew 10% year-on-year, with E-commerce expanding six times faster than in-store sales. The findings highlight a rapid shift to digital-first, AI-influenced commerce across key global markets.
As consumer expectations evolve toward convenience, personalization, and seamless digital experiences, beauty brands are under increasing pressure to adapt. From AI-powered product discovery to social commerce and livestream shopping, the path to purchase is becoming more dynamic—requiring brands to move faster and engage consumers across an increasingly complex ecosystem.
Key findings from the State of Beauty 2026 report:
- Global beauty sales grew 10% year-over-year, driven by strong digital acceleration
- E-commerce is growing 6x faster than in-store sales, reshaping channel strategies
- 49% of consumers are willing to pay more for locally made products, reflecting rising demand for authenticity and trust
- 52% will pay a premium for convenience, as time-saving solutions drive purchase decisions
- 63% of consumers prioritize mental wellness, signaling continued expansion of holistic beauty
“Beauty is entering a new phase of growth defined by both resilience and rising complexity,” Tara James Taylor, SVP, Beauty Vertical, NIQ. “Consumers are more intentional in how they spend, seeking products that deliver real value, simplicity, and wellbeing. At the same time, AI and digital commerce is transforming how consumers discover and evaluate products, shifting advantage to brands that show up clearly and consistently across digital ecosystems.”
Digital behaviors are accelerating this transformation. More than half of consumers are now exploring AI-enabled shopping tools, with 49% already receiving beauty recommendations from generative AI. Social commerce continues to gain momentum, with 53% of consumers purchasing through social platforms and 22% buying directly via TikTok Shop. In China, Livestreaming accounts for 70% of beauty sales on platforms like Douyin, underscoring the growing importance of content-driven commerce.
These shifts are redefining how products are discovered, validated, and purchased, turning online engagement into immediate conversion and driving sustained category growth.
As AI, social commerce, and digital ecosystems reshape the consumer journey, brands that invest in intuitive, transparent, and data-driven experiences will be best positioned to build trust and capture growth in the next era of beauty.
About the Report
NIQ’s State of Beauty Report 2026 is based on retail point-of-sale data across 9 categories in 52 markets, complemented by consumer panels and advanced data collection methods including web scraping to capture a comprehensive view of global beauty purchasing behavior.
To download the full review, visit: click here.
FAQ: State of Beauty 2026
What is driving growth in the global beauty market?
The global beauty market grew 10% year-over-year, driven primarily by rapid e-commerce expansion, which is growing six times faster than in-store sales. Digital channels, social commerce, and AI-enabled discovery are accelerating consumer engagement and conversion.
How is AI influencing beauty purchasing decisions?
AI is increasingly shaping how consumers discover and evaluate products. More than half of consumers are exploring AI-enabled shopping tools, and 49% already receive beauty recommendations from generative AI—helping streamline decision-making and personalize the shopping experience.
What role does social commerce play in beauty growth?
Social commerce is a major driver of category expansion. Over half of consumers (53%) now purchase through social platforms, and 22% buy directly via TikTok Shop. In markets like China, livestreaming dominates, with the majority of beauty sales on platforms like Douyin driven by live content.
What do today’s beauty consumers prioritize most?
Consumers are becoming more intentional and value-driven. Key priorities include convenience, authenticity, and wellbeing—52% are willing to pay more for convenience, 49% for locally made products, and 63% consider mental wellness essential in their beauty choices.
How should brands respond to these shifts?
Brands need to adopt digital-first, data-driven strategies that align with evolving consumer expectations. This includes investing in AI-enabled experiences, strengthening presence across social and E-commerce platforms, and delivering transparent, intuitive, and value-driven product offerings.
What makes NIQ’s data and insights unique?
NIQ combines one of the world’s most comprehensive consumer and retail datasets with advanced AI and analytics to help companies understand what consumers buy, why they buy it, and what to do next. This enables brands to move from insight to action with greater speed and confidence.
About NIQ
NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.
With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.
For more information, please visit www.niq.com.
Forward Looking Statement:
This press release on State Of Beauty 2026 report, may contain forward-looking statements regarding anticipated consumer behaviors, market trends, and industry developments. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as “expects,” “anticipates,” “projects,” “believes,” “forecasts,” “plan,” “look ahead,” “indicates”, and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.
© 2026 Nielsen Consumer LLC. All Rights Reserved.
Disclaimer: All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
NIQ-GENERAL
View source version on businesswire.com: https://www.businesswire.com/news/home/20260331204757/en/
Contacts
Media Contact:
NIQ:media.relations@niq.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press Release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press Release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press Release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press Release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press Release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom